SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
21 avr. 2022 16h01 HE
|
Scynexis
JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants...
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal
20 avr. 2022 08h30 HE
|
Scynexis
JERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
19 avr. 2022 08h30 HE
|
Scynexis
JERSEY CITY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences
04 avr. 2022 09h59 HE
|
Scynexis
JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
29 mars 2022 07h00 HE
|
Scynexis
BREXAFEMME® (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1.1 million in 2021. Fourth quarter 2021 net revenues were $0.6 million.As of the end of 2021, BREXAFEMME was...
SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
24 mars 2022 08h30 HE
|
Scynexis
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Named to Fast Company’s 2022 Top 50 List of the World’s Most Innovative Companies
08 mars 2022 08h30 HE
|
Scynexis
JERSEY CITY, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2022 17h00 HE
|
Scynexis
JERSEY CITY, N.J., March 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in Upcoming Scientific Conferences and Events
02 mars 2022 08h30 HE
|
Scynexis
JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
10 févr. 2022 07h36 HE
|
Scynexis
Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo for the primary and key secondary study...